The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of pegcetacoplan for C3G and Primary IC-MPGN

Barchart · 2d ago

STOCKHOLM, Dec. 4, 2025 /PRNewswire/ -- Sobi® (STO:SOBI) today announced that The New England Journal of Medicine (NEJM) published positive results from the Phase 3 VALIANT study investigating pegcetacoplan for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are severe and rare kidney diseases.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.